Inclusion Criteria:

          -  Ability to provide signed, written informed consent

          -  Histologically or cytologically confirmed non-metastatic adenocarcinoma of the breast
             (stage I-II)

          -  Candidate for curative-intent treatment

          -  ER+ and/or PR+ and HER2-positive (Fluorescence In Situ Hybridization-positive or 3+ by
             Immunohistochemistry staining)

          -  Life expectancy greater than 5 years

          -  Left Ventricular Ejection Fraction > 50% at baseline (within 30 days of day 0)

          -  Eastern Cooperative Oncology Group performance status ≤2

          -  Absolute Neutrophil Count >1000/µL

          -  Platelets ≥50,000/µL

          -  Hemoglobin >8.0 g/dL,

          -  Creatinine ≤3.0 x upper limit of normal (ULN)

          -  Bilirubin ≤3.0 x ULN

          -  Aspartate aminotransferase or Alanine aminotransferase <5.0 x ULN

          -  Negative serum pregnancy test for women <12 months after the onset of menopause unless
             surgically sterilized

          -  Agreement by women of childbearing potential and male participants with partners of
             childbearing potential to use a "highly effective", non-hormonal form of contraception
             or two "effective" forms of non-hormonal contraception by the patient and/or partner.

        Exclusion Criteria:

          -  Active infection

          -  Presence of known metastases (stage IV disease)

          -  Pregnant or lactating women

          -  Prior chemotherapy or radiation therapy for the primary breast cancer

          -  Concomitant malignancies or previous malignancies within the last 5 years except
             adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ
             of the cervix.

          -  History of significant cardiac disease, cardiac risk factors or uncontrolled
             arrhythmias

          -  Current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary or metabolic disease including diabetes, wound healing
             disorders, ulcers or bone fractures)

          -  Major surgical procedure or significant traumatic injury within 28 days prior to study
             treatment start or anticipated need for major surgery during the course of study
             treatment

          -  Current known infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus
             (HBV) or Hepatitis C Virus (HCV)

          -  Receipt of intravenous antibiotics for infection within 14 days prior to receiving
             study treatment

          -  Current chronic daily treatment with corticosteroids (dose >10 mg/day
             methylprednisolone equivalent) except inhaled steroids

          -  Known hypersensitivity to any of the study drugs

          -  Assessment by the investigator to be unable or unwilling to comply with the
             requirements of the protocol